SynthesisBMC pulmonary medicine2026
Bronchoalveolar lavage fluid lymphocytosis in immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICIs) enhance survival rate in non-small-cell lung cancer (NSCLC), but lead to immune-related adverse events, among which checkpoint-inhibitor pneumonitis (CIP) is a leading cause of death. The utility of bronchoalveolar-lavage (BAL) lymphocytosis for diagnosing CIP and predicting its severity remains uncertain.
methodsA systematic review and meta-analysis were conducted in accordance with PRISMA guidelines.
resultsA total of ten studies were included in the meta-analysis, comprising a total of 168 CIP samples. The pooled estimate for BAL lymphocyte percentage was 56.43% (95% CI, 43.89–68.98, I2 = 99.1%) in CIP, 14.85% (95% CI, 12.04–17.66, I2 = 9.0%) in idiopathic pulmonary fibrosis (IPF), and 43.76% (95% CI, 24.43–63.09, I2 = 99.3%) in NSCLC patients with no ICP or IPF. Significant differences were observed between CIP and IPF (p < 0.0001), NSCLC patients with no ICP or IPF (p = 0.0024). Additionally, the BAL lymphocyte percentage varied between low-grade and high-grade CIP (SMD = -1.15, 95% CI, -2.26–-0.04, I2 = 82.4%). Similar results were also calculated on the BAL lymphocyte CD4:CD8 ratio. The included studies demonstrated significant heterogeneity.
conclusionBAL lymphocyte percentage is elevated and CD4:CD8 ratio is reduced in NSCLC patients with CIP, with higher lymphocyte percentages associated with severe disease. A deeper understanding of the relationships between immunophenotyping, clinical factors and lymphocytosis will guide the use of BAL in the diagnose and evaluation of CIP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.